Form 4: NEO Exec's Stock Activity: Tax Withholding on Vesting
Insider Transaction Report
NeoGenomics Inc. EVP Alicia C. Olivo reported a routine disposition of 14 common shares to cover tax obligations related to restricted stock vesting.
Summary
- Alicia C. Olivo, Executive Vice President, General Counsel & Business Development of NeoGenomics Inc. (NEO), reported a transaction on August 1, 2025.
- The transaction involved the disposition of 14 shares of common stock, surrendered to NeoGenomics, Inc. for retirement to satisfy tax obligations associated with the vesting of restricted stock.
- Following this transaction, Ms. Olivo directly beneficially owns 49,606 shares of common stock.
- Ms. Olivo also holds a significant number of derivative securities, including various stock options with exercise prices ranging from $9.45 to $48.99, and Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) with a $0 exercise price.
- Total stock options held amount to 270,953, with various vesting and expiration dates through February 21, 2035.
- Total Restricted Stock Units (RSUs) held amount to 145,959, with vesting dates through February 21, 2025.
- Total Performance Stock Units (PSUs) held amount to 44,838 (at target performance), with potential maximum vesting of 67,258 shares based on performance criteria including share growth and revenue growth goals.
Sentiment
Score: 5
Explanation: The filing reports a routine, non-discretionary transaction related to executive compensation (tax withholding on vesting). This is a neutral event that does not indicate positive or negative operational or financial performance.
Positives
- The executive's substantial holdings of common stock (49,606 shares) and significant equity incentives (270,953 stock options, 145,959 RSUs, 44,838 PSUs at target) demonstrate strong alignment of management's interests with shareholder value.
- The disposition of shares was for tax withholding purposes, indicating the vesting of previously granted equity compensation, which is a standard and expected part of executive compensation packages.
Negatives
- No direct negatives are identified from this routine tax-related transaction.
Future Outlook
The filing does not provide forward-looking statements or guidance beyond the vesting schedules and performance criteria for equity awards.
Industry Context
This Form 4 filing details a routine insider transaction related to executive compensation, which is common across all industries for publicly traded companies. It does not provide information on broader industry trends or competitive landscape.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| EVP, GC & Business Development | NA | Alicia C. Olivo | NA | NA |
Related Party Transactions
- The disposition of 14 shares was to NeoGenomics, Inc. (the issuer) to satisfy tax obligations related to the vesting of restricted stock, which is a transaction between a company and its executive.
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine, small-scale transaction for tax purposes, not a discretionary sale. The underlying equity compensation structure aligns executive interests with shareholder value.
- Employees: No direct impact mentioned.
- Customers: No direct impact mentioned.
- Suppliers: No direct impact mentioned.
- Creditors: No direct impact mentioned.
Key Dates
| Date | Description |
|---|---|
| 2019-09-30 | Grant date for 1,394 stock options to Ms. Olivo. |
| 2020-05-01 | Grant date for 1,024 stock options to Ms. Olivo. |
| 2021-05-01 | Grant date for 516 stock options to Ms. Olivo. |
| 2021-08-01 | Grant date for 1,117 stock options to Ms. Olivo. |
| 2022-05-01 | Grant date for 22,222 stock options to Ms. Olivo. |
| 2022-09-01 | Grant date for 55,332 stock options to Ms. Olivo. |
| 2023-05-11 | Grant date for 36,508 stock options, 19,508 restricted stock units, and 19,508 performance stock units to Ms. Olivo. |
| 2024-02-23 | Grant date for 42,344 stock options, 25,330 performance stock units, and 25,329 restricted stock units to Ms. Olivo. |
| 2025-02-20 | Closing price used for calculating the premium exercise price of stock options granted on February 21, 2025. |
| 2025-02-21 | Grant date for 107,450 stock options and 63,238 restricted stock units to Ms. Olivo. |
| 2025-08-01 | Transaction date for the disposition of 14 common shares due to restricted stock vesting and tax obligations. |
| 2025-08-05 | Signature date of the reporting person on the filing. |
| 2026-01-13 | Expiration date for certain Restricted Stock Units. |
| 2026-05-11 | Expiration date for certain Performance Stock Units. |
| 2026-09-30 | Expiration date for 1,046 stock options. |
| 2027-02-23 | Expiration date for certain Performance Stock Units. |
| 2027-05-01 | Expiration date for 1,024 stock options. |
| 2028-05-01 | Expiration date for 516 stock options. |
| 2028-08-01 | Expiration date for 1,117 stock options. |
| 2029-05-01 | Expiration date for 22,222 stock options. |
| 2029-09-01 | Expiration date for 55,332 stock options. |
| 2030-05-11 | Expiration date for 36,508 stock options. |
| 2034-02-23 | Expiration date for 42,344 stock options. |
| 2035-02-21 | Expiration date for 107,450 stock options. |
Keywords
NeoGenomics, NEO, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Performance Stock Units, Executive Compensation, Tax Withholding, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.